Proactive care and early treatment help prevent serious IBD complications and improve patients’ quality of life.
In patients with psoriasis or ankylosing spondylitis, the use of interleukin (IL)-17A inhibitors, particularly secukinumab, was associated with an increased risk for inflammatory bowel disease (IBD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback